In August, Dicot is expected to take its biggest step as a development company with the planned initiation of a phase I clinical trial for the drug candidate LIB-01. Over the past quarter, the company has worked hard to strengthen both its team and finances in preparation for the study start.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.257 SEK | +3.21% | -3.02% | -19.18% |
05-06 | Dicot AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-23 | Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study | CI |
1st Jan change | Capi. | |
---|---|---|
-19.18% | 19.62M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- DICOT Stock
- News Dicot AB
- Dicot to Seek Initiation of a Phase I Clinical Trial for the Drug Candidate Lib-01